leisure time -WSS

leisure time

author：leisure time 2025-08-21 05:47:52 - browse：612

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Awakening the world to the whoosh: A patient's crusade

focus

WSS

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Analysis of telehealth claims data suggest service duplication

Stanford president faces new allegations over 1999 paper

When women are denied an abortion, their children fare worse than peers

Physician executives need more than on

Liquid biopsy for lung cancer is launched by Delfi

leisure time

leisure time

knowledge

Cancer drug shortages should be causing more outrage

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Jerome Adams on the need for new antivirals for Covid

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

ChatGPT in medicine: STAT answers readers' burning questions

DeSantis talks Trump, trans issues and 'what wokeness is'

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Senate panel eyes new effort on drug shortages

How one medical school became remarkably diverse

Tocagen's brain cancer gene therapy trial continues. Investors worry

leisure time

Indian pharmaceutical industry in denial over drug

Indian pharmaceutical industry in denial over drug

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Bill would stop addiction treatment from triggering child abuse inquiry

DeSantis talks Trump, trans issues and 'what wokeness is'

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

focus

knowledge

hotspot

Wikipedia